MacroGenics Inc
$ 1.73
-1.14%
24 Feb - close price
- Market Cap 110,702,000 USD
- Current Price $ 1.73
- High / Low $ 1.76 / 1.60
- Stock P/E N/A
- Book Value 1.06
- EPS -1.21
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.81 %
- 52 Week High 2.63
- 52 Week Low 0.99
About
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$3.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-12 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-07 | 2023-11-06 | 2023-08-09 | 2023-05-09 |
| Reported EPS | 0 | 0.27 | -0.57 | -0.65 | -0.818 | 0.9 | -0.89 | -0.84 | -0.75 | 0.28 | -0.69 | -0.61 |
| Estimated EPS | -0.2696 | -0.41 | -0.46 | -0.69 | -0.59 | 0.21 | -0.59 | -0.64 | -0.15 | -0.1 | -0.52 | 0.45 |
| Surprise | 0.2696 | 0.68 | -0.11 | 0.04 | -0.228 | 0.69 | -0.3 | -0.2 | -0.6 | 0.38 | -0.17 | -1.06 |
| Surprise Percentage | 100% | 165.8537% | -23.913% | 5.7971% | -38.6441% | 328.5714% | -50.8475% | -31.25% | -400% | 380% | -32.6923% | -235.5556% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGNX
2026-02-24 14:51:59
MacroGenics Inc (NASDAQ:MGNX) shares fell 7.4% premarket after the FDA placed a partial clinical hold on its LINNET study of lorigerlimab in gynecologic cancer patients. The hold, which prevents new patient enrollment, followed MacroGenics' notification of a temporary enrollment pause due to several Grade 4 and one Grade 5 safety events in study participants. MacroGenics stated its commitment to patient safety and to working with the FDA to resolve the hold and resume enrollment.
2026-02-24 12:51:59
MacroGenics (MGNX) experienced an 18% premarket share drop after the FDA placed a partial clinical hold on its Phase 2 LINNET study for lorigerlimab due to safety concerns, including severe adverse events and a fatality. While current participants continue treatment, new enrollments are paused. The company faces significant financial challenges, indicated by negative profitability and a distressing Altman Z-Score, despite valuation metrics suggesting potential undervaluation.
2026-02-24 11:51:59
The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET trial for lorigerlimab, an antibody-based cancer therapy, following several serious safety events in enrolled patients. While new enrollment is paused, existing patients can continue treatment. This regulatory action raises concerns about lorigerlimab's safety profile and introduces uncertainty for MacroGenics and its investors.
2026-02-23 23:51:59
The FDA has placed a partial clinical hold on MacroGenics' (NASDAQ: MGNX) Phase 2 LINNET study for lorigerlimab in gynecologic cancers, pausing new patient enrollment due to serious safety events, including Grade 4 thrombocytopenia, myocarditis, and a Grade 5 neutropenia with septic shock incident. Existing patients can continue treatment, and MacroGenics plans to work with the FDA to resolve the hold. This development raises concerns about the drug's risk-benefit profile, prompting an oncology analyst to flag meaningful safety issues.
2026-02-23 22:51:59
MacroGenics Inc. (NASDAQ:MGNX) shares are down following a partial clinical hold placed by the FDA on its Phase 2 LINNET study for lorigerlimab due to safety concerns, including one patient death. This setback comes after a previous trial in May 2024 also reported several deaths. The company is working with the FDA to resolve the issues and aims to resume enrollment.
2026-02-23 22:51:59
MacroGenics has announced a partial clinical hold by the FDA on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, following a temporary pause in enrollment due to safety events. The partial hold means no new patients will be enrolled, but current participants can continue receiving the study drug. MacroGenics is committed to working with the FDA to resolve the hold and resume enrollment as soon as possible.
